Hints and tips:
Related Special Reports
...A number of celebrity endorsements and the success of Novo Nordisk and Eli Lilly’s treatments in helping users lose weight have made the drugs hugely popular, sparking supply shortages....
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...A decision on Eli Lilly’s donanemab drug from the US Food and Drug Administration was originally due by the end of the first quarter, but the medicine will now be subject to a further review by an advisory...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...The FDA, which declined to comment, is expected to take several months to convene the panel of experts, according to a person close to Eli Lilly....
...The retail giant struck a deal earlier this month to dispense medication on behalf of Zepbound maker Eli Lilly’s direct-to-consumer service LillyDirect....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...Dear reader, It isn’t often that a company pays good money to criticise customers for buying its product. But that is what Eli Lilly did this week....
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...After the MHRA announced authorisation of Eli Lilly’s “KwikPen” on Thursday, a format that provides four doses in one device, the company has said it will now be able to supply the drug to England, Scotland...
...Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers to dominate...
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
...Eli Lilly’s share price fell as much as 2.4 per cent in early US trading before later recovering its losses....
...Eli Lilly lowered its expectations for full-year earnings because of accounting charges related to recent acquisitions, despite beating expectations in the third quarter driven by growth in diabetes and...
...Eli Lilly’s $12.50 a share cash offer for Point represents a 50 per cent premium to the stock’s undisturbed three month average....
...Regulators on both sides of the Atlantic have cleared Eli Lilly’s injectable diabetes medication for use as a weight loss treatment, creating the first direct rival to Wegovy, Novo Nordisk’s obesity drug...
...Novo Nordisk and Eli Lilly have broken records for deals for weight-loss drugs this year, buying a series of biotechs in a bid to ensure that their dominance in the fast-growing market lasts for years....
...Eli Lilly has agreed to buy cancer biotech Point Biopharma for about $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price amid a severe cash crunch in the biotech industry....
...Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price....
...The developer of a rival weight-loss treatment to those offered by Novo Nordisk and Eli Lilly said its drug had achieved positive results in liver disease trials, showing how a new class of obesity drugs...
...Novo Nordisk, Eli Lilly’s Danish rival, has also soared. But investors who were hoping for a more general broadening of market gains have so far been disappointed....
...Citi expects Nvidia and Eli Lilly alone will make up a quarter of S&P 500 earnings growth in 2024. How’s everyone feeling about this rally? Email us: robert.armstrong@ft.com and ethan.wu@ft.com....
...Eli Lilly shares hit a record high after the pharmaceuticals group upgraded its 2023 revenue and profit forecasts following a surge in sales of its new diabetes and weight-loss drug Mounjaro....
International Edition